We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets open in 2 hrs 9 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.33-0.65 (-2.50%)
At close: 4:00PM EDT
Full screen
Previous Close25.98
Open26.01
Bid0.00 x 800
Ask35.00 x 800
Day's Range24.85 - 26.10
52 Week Range13.30 - 26.74
Volume17,071
Avg. Volume53,784
Market Cap573.084M
Beta0.13
PE Ratio (TTM)N/A
EPS (TTM)-4.44
Earnings DateApr 26, 2018 - Apr 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.59
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Merus Announces Annual Meeting of Shareholders

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the `Investor Relations` section of Merus` website (www.merus.nl) under "Financial Information". Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®.

  • GlobeNewswire11 days ago

    Merus Announces Annual Meeting of Shareholders

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of China ...

  • GlobeNewswire2 months ago

    Merus to Present at the Jefferies 2018 Healthcare Conference

    UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today ...

  • GlobeNewswire2 months ago

    Merus to Present at the Jefferies 2018 Healthcare Conference

    UTRECHT, The Netherlands, May 31, 2018-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Hui Liu, Ph.D., Executive Vice ...

  • GlobeNewswire2 months ago

    Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018.

  • GlobeNewswire2 months ago

    Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018.

  • GlobeNewswire2 months ago

    Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

    "This study demonstrates the power of empirical functional screening to unlock innovative biology unique to the bispecific antibody format," said Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer of Merus. Using unbiased combinatorial screening, we identified a bispecific antibody that employs a unique mechanism to selectively and potently block signaling down this pathway (Dock & Block(TM)). The development candidate advanced from this work, MCLA-128, is being evaluated in multiple clinical studies where this pathway is believed to drive tumor growth and resistance to existing standard of care therapies.

  • GlobeNewswire2 months ago

    Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

    “This study demonstrates the power of empirical functional screening to unlock innovative biology unique to the bispecific antibody format,” said Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer of Merus. Using unbiased combinatorial screening, we identified a bispecific antibody that employs a unique mechanism to selectively and potently block signaling down this pathway (Dock & Block™). The development candidate advanced from this work, MCLA-128, is being evaluated in multiple clinical studies where this pathway is believed to drive tumor growth and resistance to existing standard of care therapies.

  • ACCESSWIRE2 months ago

    Blog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and Canada

    LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VVUS as the Company's latest news hit the wire. On May 01, 2018, the Company announced that it has inked an agreement to acquire all of the product rights for Janssen Pharmaceuticals, Inc.'s PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada, for approximately $135 million.